VolitionRX Limited (NYSEAMERICAN:VNRX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of VolitionRX Limited (NYSEAMERICAN:VNRX) have earned an average recommendation of “Moderate Buy” from the five analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $2.3333.

Several equities research analysts have issued reports on the company. HC Wainwright cut their price target on VolitionRX from $1.50 to $1.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a report on Monday. Finally, Citigroup downgraded VolitionRX to a “hold” rating in a research report on Monday.

VolitionRX Stock Down 6.6%

Shares of NYSEAMERICAN:VNRX traded down $0.01 during midday trading on Monday, reaching $0.17. The company had a trading volume of 856,209 shares, compared to its average volume of 9,771,458. The business’s 50 day moving average price is $0.20 and its 200 day moving average price is $0.29. The stock has a market cap of $26.47 million, a PE ratio of -0.76 and a beta of 1.33. VolitionRX has a 1-year low of $0.15 and a 1-year high of $0.94.

VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Tuesday, March 31st. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). The company had revenue of $0.45 million during the quarter, compared to analyst estimates of $0.71 million. On average, research analysts expect that VolitionRX will post -0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VolitionRX

Several institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of VolitionRX during the 3rd quarter worth approximately $28,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of VolitionRX during the 2nd quarter worth approximately $52,000. Jane Street Group LLC acquired a new stake in VolitionRX during the fourth quarter worth approximately $28,000. Squarepoint Ops LLC acquired a new stake in VolitionRX during the fourth quarter worth approximately $34,000. Finally, Citadel Advisors LLC grew its position in VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after buying an additional 135,775 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.